- Home
- Grants
- Competitive research grants
- CS Individual Research Grant
CS Individual Research Grant
01 Jul 2025 - 08 Aug 2025
On this page
Please note that the last grant call under RIE2025 will be the July 2025 grant call. There is no planned grant call in January 2026. Subject to approval of the RIE2030 framework, the first grant call under RIE2030 is expected to be launched in July 2026.
About
The Clinician Scientist-Individual Research Grant (CS-IRG) is provided to Clinician Scientists (CS) to enable them to carry out medical research on a specifically defined topic for a period of 3-5 years in local public institutions. All CS-IRG applications will be evaluated through a single-stage review process by the Review Panel (RP).
Research theme
The CS-IRG is open to application on all research themes. Applications are assessed based on scientific merit at the international level and relevance to Singapore, but should prioritisation be required between meritorious applications, the following seven disease areas have been identified as national priorities for research:
Cancers and neoplasms
Cardiovascular
Eye
Infection
Mental health
Metabolic and endocrine
Neurological
Evaluation criteria
Selection of successful proposals would be based on the following evaluation criteria:
Scientific excellence
Feasibility of study in local context
Productivity
Overall impact in local context
Track record of investigators
Eligibility Criteria for CS-IRG
Each CS-IRG application must be led by a Clinical Principal Investigator (PI) who has to fulfill the eligibility criteria listed below:
PI must be clinically qualified (i.e. with MD/MBBS/BDS) and preferably with post-graduate clinical training and experience.
Allied Health Professionals who meet the following conditions may apply:
Non-medically trained PIs who are nurses, pharmacists or other allied health professions listed on this website in clinical practice, doing research in clinical settings or doing research with clinical and healthcare applications/relevance, are eligible to apply.
Applicants who are working in human clinical research, including epidemiologists, biostatisticians, and whose research is clinically relevant and has potential health impact, will be considered as exceptions on a case-by-case basis.
Non-medically trained applicants conducting wet laboratory based research are not eligible.
Applicants must possess a minimum academic qualification of a PhD or the equivalent training.
Recipients of NMRC Human Capital Awards, Transition Award and NMRC Research Training Fellowship are eligible to apply.
A*STAR CS scholar from the National Science Scholarship (NSS) (MBBS-PhD) or NSS (MD-PhD) schemes and who fulfil the following may apply:
hold primary appointments in Academic Medical Centres (AMCs), public health institutions (PHIs) or medical schools; or
hold primary appointments in A*STAR but (with mutual agreement of A*STAR and the AMC/PHI/medical school) also hold a joint appointment in the AMC/PHI/medical school, provided that any such grant application is supported by the AMC/PHI/medical school.The institution/school should also consider if these A*STAR CS scholars are able to demonstrate that they can act as a bridge between A*STAR and the healthcare system.
submit the grant application through AMCs/PHIs/medical schools as host institutions.
For proposals involving patients, the clinical PI or co-I should be SMC registered; or should be able to demonstrate ability to access patients through SMC registered collaborators. For some CS-IRG proposals it is recognized that some studies may be pre-clinical and not require the PI to be SMC registered.
Only one PI is allowed per application. The number of applications by an individual (as PI) is capped at 1 grant application per grant type in a grant call.
Additional eligibility criteria include
Hold a primary appointment in a local public hospital/public health institutions/national specialty centre/public universities/Academic Medical Centres and salaried by the institution.
Be an independent PI with a demonstrated track record of research as evidenced by the award of nationally competitive funding (international funding to be considered on a case by case basis) or substantial publication record.
Have a laboratory or clinical research program that carries out research in Singapore.
Hold a minimum of 9 months employment with a local public institution. Upon award, the PI must agree to fulfill at least 6 months of residency in Singapore for each calendar year over the duration of the grant award.
No outstanding reports from previous BMRC, NMRC grants and other national grants.
Grant call frequency
There will be two grant calls per year (Jan and Jul).
Funding quantum
The CS-IRG will provide a funding quantum of up to S$1.95M per project (inclusive of up to 30% indirect costs^) for up to 3 years. Projects involving prospective patient/subject recruitment may apply for up to 5 years.
^Indirect costs is not applicable for research scholarship budget
Submission
The RIE2025 CS-IRG grant call is closed.
Review panel
The composition of the CS-IRG Review Panel 2024-2026 is listed in the table below.
CS-IRG Review Panel 2024-2026
S/N | Name | Institution |
---|---|---|
1 | Prof Yap Seng CHONG (Co-Chair) | Dean, Yong Loo Lin School of Medicine, National University of Singapore Lien Ying Chow Professor in Medicine, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore Deputy Chief Executive (Education & Research), National University Health System Chief Clinical Officer, Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR) |
2 | Prof Joseph SUNG | Distinguished University Professor Dean, Lee Kong Chian School of Medicine Senior Vice President (Health and Life Sciences), Nanyang Technological University, Singapore |
3 | A/Prof Rinkoo DALAN | Senior Consultant, Endocrinology, TTSH Associate Professor, Lee Kong Chian School of Medicine, NTU |
4 | A/Prof Chester DRUM | Associate Professor and Senior Consultant, Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore |
5 | Prof Derek HAUSENLOY | Professor, Duke-NUS Medical School Senior Consultant Cardiologist and Clinician Scientist, National Heart Centre, Singapore |
6 | Prof Gopal IYER | Head & Senior Consultant, Division of Surgery & Surgical Oncology, National Cancer Centre Singapore Senior Consultant, SingHealth Duke-NUS Head and Neck Centre Head & Senior Consultant, Head & Neck Surgery, Singapore General Hospital |
7 | Prof Ecosse LAMOUREUX | Professor, SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Programme Director of the Population Research and Clinical Epidemiology platform, Singapore Eye Research Institute |
8 | Prof Soo Chin LEE | Head & Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore |
9 | A/Prof Kandiah NAGAENDRAN | Associate Professor of Neuroscience, Lee Kong Chian School of Medicine, Nanyang Technological University Senior Consultant, Department of Neurology, National Neuroscience Institute Director, Clinical Research, Neuroscience Academic Clinical Programme |
10 | A/Prof Joanne NGEOW | Associate Professor, Genomic Medicine, Lee Kong Chian School of Medicine Associate Professor, Lee Kong Chian School of Medicine Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore |
11 | Prof Ee Chee REN | Adjunct Associate Professor |
12 | A/Prof Vijay K SHARMA | Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore. Senior Consultant, Division of Neurology, Department of Medicine, National University Hospital |
13 | Prof Yik Ying TEO | Dean, Saw Swee Hock School of Public Health, NUS Department of Statistics and Applied Probability, Faculty of Science, NUS |
14 | A/Prof Sunny Hei WONG | Associate Professor of Nutrition, Digestion and Metabolism, Academic Medicine, Lee Kong Chian School of Medicine Assistant Dean, Academic Medicine, Lee Kong Chian School of Medicine |
15 | A/Prof Barnaby Edward YOUNG | Head, Infectious Disease Research Ward; Senior Consultant, National Centre for Infectious Diseases |
16 | Prof Ian CAMPBELL | Co-Head, Women’s Cancer Program, Peter MacCallum Cancer Centre Head, Cancer Genetics Laboratory, Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia Principal Investigator, Lifepool |
17 | Prof Bernard CHEUNG | Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics Chief, Division of Clinical Pharmacology & Therapeutics, Department of Medicine, University of Hong Kong, Hong Kong |
18 | Prof Mark COOPER | Head of Department of Diabetes, Central Clinical School, Monash University, Australia |
19 | Prof Masaru KATOH | Doctorate, National Cancer Centre, Tokyo, Japan |
20 | Prof Thomas KLIMKAIT | Project Leader, University of Basel, Switzerland |
21 | Prof Linda LAM | Professor and Chairman, Department of Psychiatry, The Chinese University of Hong Kong (CUHK), Hong Kong |
22 | Prof Andrew LOTERY | Professor of Ophthalmology, University of Southampton, United Kingdom |
23 | Prof Andreas MOLLER | Professor, Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong (CUHK), Hong Kong |
24 | Prof Guang NING | Professor, Ruijin Hospital, Shanghai Jiao Tong University of Medicine, China |
25 | Prof Matthias OCKER | Faculty member and adjunct professor of experimental medicine, Charité University Medicine Berlin, Germany Department of Hematology, Oncology and Cancer Immunology (CCM) Vice President of Translational Medicine, Anji Pharma |
26 | Prof Kyong Soo PARK | Director, Center for Precision Medicine, Seoul National University, Korea |
27 | Prof Takeshi SAKURAI | Professor of Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Japan |
28 | Prof Mark SCHEMBRI | Professor, School of Chemistry and Molecular Biosciences, The University of Queensland, Australia |
29 | Prof Gerald TANNOCK | Emeritus Professor, University of Otago, New Zealand |
Applicants are not allowed to approach any of the panel members to discuss or solicit information related to their application review or funding decisions. NMRC may impose a suspension and/or debarment on such applicants.